Research progress in lipid-lowering drugs: PCSK9 inhibitor Inclisiran

The incidence of cardiovascular events is increasing year by year, among which dyslipidemia is one of the most common risk factors. With the advent of statins 40 years ago, human beings have opened a new era of prevention and treatment of dyslipidemia. However, individual differences, adverse reactions and “6% effect of statins” restrict the benefits of patients. The discovery of PCSK9 provides a new idea for the control of blood lipids. Two kinds of PCSK9 monoclonal antibodies: Alirocumab and Evocumab have been listed on the market. In recent years, Inclisiran, a drug that uses RNA interference (RNAi) technology, has also entered the phase of III clinical trials. This paper reviews the pharmaceutical properties and clinical trial results of Inclisiran to show the safety and efficacy of Inclisiran.